Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
61-75 of 422
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Project Oncology®Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP
Andrew E. Hendifar, MD
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS
Chandrikha Chandrasekharan, MBBS
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and HematologyDESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
- advertisement
Optimizing Treatment Intensity in Early-Stage TNBC
Project Oncology®Optimizing Treatment Intensity in Early-Stage TNBC
Roberto Leon-Ferre, MD
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Project Oncology®Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Charles Turck, PharmD, BCPS, BCCCP
Matthew Hadfield, MD
Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Project Oncology®Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Roberto Leon-Ferre, MD
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Project Oncology®Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Jacob Sands, MD
Joseph O. Jacobson, MD
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Project Oncology®Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Amy Comander, MD
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Project Oncology®Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Amy Comander, MD
- advertisement
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Project Oncology®DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Daniel Hertz, PhD, PharmD
Managing Immunotherapy Toxicities in Lung Cancer Patients
Spotlight on Lung CancerManaging Immunotherapy Toxicities in Lung Cancer Patients
Jacob Sands, MD
Aliyah Pabani, MD
Matching TNBC Treatment Intensity to Patient Needs
Project Oncology®Matching TNBC Treatment Intensity to Patient Needs
Roberto Leon-Ferre, MD
